IP Library Granted Patent US 7,608,605
Granted Patent B2
US 7,608,605 · App. 12/356,513 · Granted Oct 27, 2009

Pharmaceutical composition

Assignee: CPEX Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,608,605
App. No.
12/356,513
Granted
Oct 27, 2009
Kind
B2
Abstract

A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

Claims (3)

1. A method for maintaining a therapeutically effective concentration of testosterone in the blood serum of a male for treating hypogonadism which comprises transdermally delivering to the male by applying to the skin a composition which is in the form of a topical gel, which has a viscosity of about 2000 to about 6000 cps and a pH of about 4 to about 8, and comprises: (A) about 0.1 to about 5 wt. % of testosterone; (B) about 0.5 to about 15 wt. % of oxacyclohexadecan-2-one; (C) about 1 to about 6 wt. % of a thickening agent; (D) a mixture of solvents which include: (i) about 60 to about 75 wt. % of ethanol or isopropanol; and (ii) propylene glycol and glycerin as co-solvents; and (E) a crystallization inhibitor comprising polyethylene glycol.

2. The method of claim 1 wherein the polyethylene glycol ranges from about 0.001 to about 5 wt. %.

3. The method of claim 2 wherein said composition is maintained on said skin for a period of time sufficient for delivery of the testosterone to the body of the male and is applied to the skin in the form of a unit dose which contains about 1 to about 300 mg of testosterone and such that, following a single application of the unit dose to the skin, the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the male achieved in the 24-hour period following the application is about 100 to about 35,000 ng.h/dL greater than the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the male than would have been achieved in the same 24-hour period had the dose not been administered.

Assignments (5)
NOTICE OF ASSIGNMENT OF SECURITY INTEREST (INTELLECTUAL PROPERTY) Recorded Jun 30, 2017
From: THE BANK OF NEW YORK MELLON, AS EXISTING AGENT
To: GLAS AMERICAS LLC, AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 043065/0713 →
SECURITY INTEREST Recorded May 7, 2014
From: FCB I LLC
To: THE BANK OF NEW YORK MELLON
Reel/Frame 032843/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2011
From: CPEX PHARMACEUTICALS, INC.
To: FCB I LLC
Reel/Frame 026075/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: GYURIK, ROBERT J.
To: BENTLEY PHARMACEUTICALS, INC.
Reel/Frame 022924/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: BENTLEY PHARMACEUTICALS, INC.
To: CPEX PHARMACEUTICALS, INC.
Reel/Frame 022924/0083 →
Continuity (4)
Continuation 1193180900 · Oct 31, 2007
Continuation 1047372400
Provisional Application 6037410300 · Apr 19, 2002
Related Publication 20090118250A1 · May 7, 2009